drugset / Trial / NCT06890897

Esketamine Combined Pulsed Radiofrequency for Acute/Subacute Zoster-associated Trigeminal Neuralgia

NCT06890897

RandomizedParallel-groupSingle-blindTreatment

Summary

To assess the 1-month effects and safety of esketamine combined PRF and standardized treatment to relieve pain in patients with acute/subacute zoster-related trigeminal neuralgia(ZRTN).

Timeline

Start
2025-04-01
Primary completion
2026-06-30
Completion
2026-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Esketamine Other / unclassified 8 mg Intravenous

Indications